 Carcinoma, Non-Small-Cell Lung
"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
| Descriptor ID |
D002289
|
| MeSH Number(s) |
C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
|
| Concept/Terms |
Carcinoma, Non-Small-Cell Lung- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non Small Cell Lung
- Carcinomas, Non-Small-Cell Lung
- Lung Carcinoma, Non-Small-Cell
- Lung Carcinomas, Non-Small-Cell
- Non-Small-Cell Lung Carcinomas
- Nonsmall Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".
This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 5 | 3 | 8 | | 1997 | 9 | 4 | 13 | | 1998 | 6 | 2 | 8 | | 1999 | 4 | 1 | 5 | | 2000 | 7 | 1 | 8 | | 2001 | 7 | 2 | 9 | | 2002 | 16 | 3 | 19 | | 2003 | 12 | 0 | 12 | | 2004 | 16 | 2 | 18 | | 2005 | 18 | 3 | 21 | | 2006 | 18 | 4 | 22 | | 2007 | 18 | 1 | 19 | | 2008 | 17 | 3 | 20 | | 2009 | 14 | 1 | 15 | | 2010 | 26 | 2 | 28 | | 2011 | 16 | 2 | 18 | | 2012 | 36 | 2 | 38 | | 2013 | 30 | 9 | 39 | | 2014 | 34 | 2 | 36 | | 2015 | 36 | 2 | 38 | | 2016 | 35 | 1 | 36 | | 2017 | 41 | 0 | 41 | | 2018 | 44 | 2 | 46 | | 2019 | 39 | 1 | 40 | | 2020 | 30 | 2 | 32 | | 2021 | 34 | 0 | 34 | | 2022 | 58 | 0 | 58 | | 2023 | 36 | 1 | 37 | | 2024 | 26 | 3 | 29 | | 2025 | 29 | 1 | 30 | | 2026 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
Martin-Martin A, Chipón C, Guzman-Kunstmann C, Guzman-Kunstmann S, Buelvas N, Henríquez C, Vidal F, Villarroel-Espindola F, Hinz TK, Heasley LE, López-Muñoz RA. The polyamine inhibitor SAM486A increases the efficacy of adagrasib in non-small cell lung cancer cells harboring KRASG12C mutation. Biol Res. 2026 Feb 19; 59(1).
-
He K, Forde PM, Govindan R, Santoro A, Gettinger S, Borghaei H, Spira A, Chu Q, Zinner R, Schoenfeld AJ, Camidge DR, Spigel DR, Gurpide A, Juergens RA, Laurie SA, Cerra M, Spires T, Greenawalt DM, Rapoport I, Gainor JF. Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung). ESMO Open. 2026 Mar; 11(3):106078.
-
Sivarajkumar S, Edupuganti S, Lazris D, Bhattacharya M, Davis M, Dressman D, Thomas R, Hu Y, Ren Y, Xu H, Yang P, Huang Y, Wang Y. Extraction of Treatments and Responses From Non-Small Cell Lung Cancer Clinical Notes Using Natural Language Processing. JCO Clin Cancer Inform. 2026 Jan; 10:e2500138.
-
Waliany S, Roy SG, Pecci F, Weber UM, Sun F, Arter Z, Lomibao M, Alessi JV, Nishino M, Luo F, Repetto M, Falcon C, Do A, Peterson J, Liang J, Liu A, Nagasaka M, Ricciuti B, Drilon A, Ou SI, Neal JW, Patil T, Awad M, Yeap BY, Digumarthy SR, Lin JJ. Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study. J Natl Compr Canc Netw. 2025 Nov 19; 23(12):522-530.
-
Bar J, Cai MH, Choi YC, Baijal S, Zhao W, Liede A, Vasilopoulos A, Roberts-Rapp L, Jiang F, Simmons A, Ratajczak C, Lu S, Ansell PJ, Camidge DR. Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer. Acta Oncol. 2025 11 18; 64:1544-1553.
-
Mott NM, Meguid RA, Randhawa SK, David EA, Mitchell JD, Stuart CM. Social Vulnerability is Associated with Significant Delays to Definitive Surgery for Stages IA to IIIA Non-small Cell Lung Cancer and Consequential Increased Rates of Pathologic Upstaging. Ann Surg Oncol. 2026 Feb; 33(2):858-870.
-
Shimizu T, Ohkuma R, Homma M, Nakayama S, Sasaki Y, Muto S, Ieguchi K, Watanabe M, Taguchi A, Takayanagi D, Wada Y, Horiike A, Kubota Y, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Mura E, Yoshimura K, Tsuji M, Kiuchi Y, Suzuki H, Yamochi T. Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression. Front Immunol. 2025; 16:1528594.
-
Riely GJ, Wood DE, Aisner DL, Loo BW, Axtell AL, Bauman JR, Bharat A, Chang JY, Desai A, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Levy B, Lin J, Lovly CM, Maldonado F, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Mendez ALR, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yau E, Gregory K, Hang L. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025. J Natl Compr Canc Netw. 2025 Sep; 23(9):354-362.
-
Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo EC, Pancirer D, Das M, Ellis-Caleo TJ, Cheung JM, Lin JJ, Watson AS, Camidge DR, Sridhar A, Parikh K, Crowley F, Marron TU, Aggarwal V, Ahmed M, Sankar K, Kawtharany H, Zhang J, Owen DH, Li M, Nagasaka M, Pinato DJ, Awosika N, Alhamad K, Puri S, Zaman U, Gupta DM, Lau C, Khan H, Liauw J, Velazquez AI, Brown T, Moliner L, Mosteiro M, Rocha P, Evans M, Vanderwalde A, Elliott A, Nieva J, Lopes G, Ma PC, Borghaei H, Lee M, Young L, Aljumaily R, Mirza H, Kwiatkowski DJ, Herbst RS, Flavell RA, Naqash AR, Chiang AC. Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma. Nat Commun. 2025 Aug 19; 16(1):7717.
-
Muro K, Feinstein T, Baranda J, Bonta I, Yanagitani N, Gersten T, Gandhi L, Kudo T, Fujioka N, Kaplan J, Gorla S, Liu S, Wozniak M, Poondru S, Dillon R, Meng C, Patil T. Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study. Eur J Cancer. 2025 Sep 09; 227:115603.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|